Lumping and splitting of fibrotic interstitial lung diseases

Symposium
Chairs: M. Kolb (Hamilton (ON), Canada), V. Poletti (Forlì, Italy)
Aims: to compare big-picture approaches for future clinical practice, pathogenetic approaches and treatment algorithms in fibrotic interstitial lung diseases (ILDs) and to contrast the goal of increasing diagnostic and prognostic precision for development of personalised medicine (e.g., for sub-groups of patients with idiopathic pulmonary fibrosis [IPF]) with the amalgamation of various forms of progressive fibrotic ILDs (progressive fibrotic phenotype).

Personalised pathogenetic pathways in fibrotic ILDs: the yin of pathogenetic thinking M. Molina Molina (Barcelona, Spain)
Pathogenetic mechanisms common to disease progression in fibrotic ILDs: the yang of pathogenetic thinking K. Antoniou (Heraklion, Greece)
The progressive fibrotic phenotype in ILDs: can it be reliably recognised at baseline evaluation? K. Brown (Denver, United States of America)
The progressive fibrotic phenotype in fibrotic ILDs: the critical importance of observed disease behaviour A. Wells (London, United Kingdom)